Mansoura University Ivermectin-based Study Results in Superior Viral Clearance & Peer Review Status in Journal of Medical Virology

Mansoura University Ivermectin-based Study Results in Superior Viral Clearance & Peer Review Status in Journal of Medical Virology

Back in May 2020, TrialSite announced the study titled a pilot clinical trial led by Egypt’s Mansoura University, located in the middle of the Nile Delta region. A highly ranked academic medical research center within this Middle East nation, a team of investigators there led by two doctors and faculty of medicine professors, sought to test whether the combination of Nitazoxanide, Ribavirin, zinc and Ivermectin clears SARS-CoV-2, the virus behind COVID-19? With results now published in the peer reviewed Journal of Medical Virology, the team has an answer. Disclosed initially as both a randomized and sequential clinical trial (later declared non-randomized), the authors were able to enroll 62 in the combination, Ivermectin-based arm and 51 on the standard of care or “supportive therapy.” Those COVID-19 patients in the Ivermectin-based treatment group fared far better. By Day 7, while there was 0% clearance in the standard of care group, 58.1% of the combination Ivermectin-based group experienced viral clearance. By Day 15, 73.1% of the Ivermectin-based arm were fully cleared of SARS-CoV-2 while only 13.7% of those on the standard of care were cleared of the virus.  The cumulative c...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee